Structure Therapeutics Q3 2026: Net Loss Widens to $144.8M, $1.2B Cash Through 2028
GPCR is trading near its 52-week low of $18.7 (14% above the low).
Summary
Structure Therapeutics posted a Q3 2026 net loss of $144.8M versus $65.7M a year earlier on rising Phase 3 costs, backed by $1.2B in cash it says funds operations through 2028. The 10-Q also discloses the CTO's resignation and a new Chief Commercial Officer's compensation package.
Key Events · Earnings and Guidance · GPCR
-
Q3 Net Loss Widens to $144.8M
Net loss was $144.8M versus $65.7M in Q3 2025, including $12.7M of non-cash share-based compensation.
-
R&D Spend Nearly Doubles
R&D rose to $134.6M from $59.0M a year earlier on clinical trial, preclinical and employee costs; G&A rose to $21.8M from $14.8M.
-
$1.2B Cash Funds Operations Through 2028
Cash, cash equivalents and short-term investments totaled $1.2B at September 30, 2026, down from $1.3B at June 30, 2026, funding milestones through end-2028 excluding pre-commercialization costs.
-
Phase 3 Topline Slated for 2H 2028
ACCOMPLISH-1 (up to 3,600 patients) and ACCOMPLISH-2 (up to 1,100 patients with T2DM) are enrolling; topline data expected in the second half of 2028.
Analysis · GPCR · Life Sciences
The Q3 loss nearly doubled year over year as Phase 3 spending on aleniglipron ramped, but the $1.2B cash pile funds operations and key clinical milestones through end-2028, so there is no near-term financing pressure. The filing also discloses a CTO resignation effective November 13, 2026 and the terms of a new Chief Commercial Officer hire, both governance items investors will weigh against the clinical timeline.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GPCR was trading at $21.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.70 to $94.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.